Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular endothelial growth factor: basic science and clinical progress.

Napoleone Ferrara1

  • 1Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. nf@gene.com

Endocrine Reviews
|August 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways.

Nature communications·2025
Same author

Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Development of an Open-Source Dataset of Flat-Mounted Images for the Murine Oxygen-Induced Retinopathy Model of Ischemic Retinopathy.

Translational vision science & technology·2024
Same author

Elucidating VEGF Biology: A Journey of Discovery and Clinical Translation.

Arteriosclerosis, thrombosis, and vascular biology·2024
Same author

Report from the 2023 workshop on endothelial permeability, edema and inflammation.

Nature cardiovascular research·2024
Same journal

Sex Hormones & Exercise in the Musculoskeletal System: From Signaling to Structure and Function.

Endocrine reviews·2026
Same journal

DAX-1 in sex determination and gonadal development: revisiting the anti-testis hypothesis.

Endocrine reviews·2026
Same journal

Regulators of Appetite in Mammals - Old and New players.

Endocrine reviews·2026
Same journal

Endometriosis-associated Pain: Mechanism, Neuroimmune Signature, and Translational Precision Strategies.

Endocrine reviews·2026
Same journal

Nuclear Receptors Shape Sepsis Pathophysiology.

Endocrine reviews·2026
Same journal

Beyond aldosterone and renin: emerging biomarkers for diagnosing and subtyping primary aldosteronism.

Endocrine reviews·2026
See all related articles

Vascular endothelial growth factor (VEGF) drives blood vessel growth and is crucial for development and disease. Inhibiting VEGF shows promise in treating cancers and eye conditions like macular degeneration.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, essential for both normal development and pathological conditions.
  • Hypoxia is a primary stimulus for VEGF gene transcription, highlighting its role in cellular response to low oxygen.
  • VEGF exerts its functions through high-affinity tyrosine kinase receptors, Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2).

Purpose of the Study:

  • To elucidate the multifaceted roles of VEGF in angiogenesis, from embryonic development to pathological processes.
  • To review the evidence implicating VEGF in tumor angiogenesis and its potential as a therapeutic target.
  • To highlight the clinical advancements in VEGF inhibition for cancer treatment and other neovascular diseases.

Main Methods:

Related Experiment Videos

  • Review of existing literature on VEGF function, gene regulation, and receptor interactions.
  • Analysis of studies demonstrating VEGF's role in developmental, reproductive, and bone angiogenesis.
  • Examination of in situ hybridization data showing VEGF mRNA expression in human tumors.
  • Evaluation of preclinical studies using anti-VEGF agents against tumor cell lines.
  • Consideration of clinical trial outcomes and FDA approvals for VEGF inhibitors.

Main Results:

  • VEGF is critical for vascularization, with loss of a single allele causing embryonic lethality.
  • VEGF mRNA is expressed in most human tumors, and anti-VEGF therapies inhibit tumor growth in vivo.
  • VEGF inhibitors, including bevacizumab, are approved for treating metastatic colorectal cancer and are under investigation for other malignancies.
  • VEGF is implicated in intraocular neovascularization, such as in diabetic retinopathy and age-related macular degeneration.

Conclusions:

  • VEGF is a central mediator of angiogenesis with critical roles in development and disease.
  • Targeting VEGF with inhibitors represents a significant therapeutic strategy for various cancers and neovascular eye diseases.
  • Ongoing research and clinical trials continue to explore the full potential of VEGF-targeted therapies.